atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_implant,DDD_intravesical,DDD_N,DDD_O,DDD_P,unit_implant,unit_intravesical,unit_N,unit_O,unit_P
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA01,cyclophosphamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA02,chlorambucil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA03,melphalan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA05,chlormethine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA06,ifosfamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA07,trofosfamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA08,prednimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA09,bendamustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AA,Nitrogen mustard analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AA10,melphalan flufenamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB01,busulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB02,treosulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AB,Alkyl sulfonates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AB03,mannosulfan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC01,thiotepa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC02,triaziquone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AC,Ethylene imines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AC03,carboquone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD01,carmustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD02,lomustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD03,semustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD04,streptozocin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD05,fotemustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD06,nimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD07,ranimustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AD,Nitrosoureas,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AD08,uramustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AG,Epoxides,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AG01,etoglucid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX01,mitobronitol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX02,pipobroman,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX03,temozolomide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01A,ALKYLATING AGENTS,L01AX,Other alkylating agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01AX04,dacarbazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA01,methotrexate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA03,raltitrexed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA04,pemetrexed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BA,Folic acid analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BA05,pralatrexate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB02,mercaptopurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB03,tioguanine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB04,cladribine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB05,fludarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB06,clofarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BB,Purine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BB07,nelarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC01,cytarabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC02,fluorouracil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC03,tegafur,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC04,carmofur,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC05,gemcitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC06,capecitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC07,azacitidine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC08,decitabine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC09,floxuridine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC52,"fluorouracil, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC53,"tegafur, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC58,"decitabine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01B,ANTIMETABOLITES,L01BC,Pyrimidine analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01BC59,"trifluridine, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA01,vinblastine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA02,vincristine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA03,vindesine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA04,vinorelbine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA05,vinflunine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CA,Vinca alkaloids and analogues,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CA06,vintafolide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CB,Podophyllotoxin derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CB01,etoposide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CB,Podophyllotoxin derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CB02,teniposide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CC,Colchicine derivatives,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CC01,demecolcine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD01,paclitaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD02,docetaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD03,paclitaxel poliglumex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD04,cabazitaxel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CD,Taxanes,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CD51,paclitaxel and encequidar,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE01,topotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE02,irinotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE03,etirinotecan pegol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CE,Topoisomerase 1 (TOP1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CE04,belotecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01C,PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS,L01CX,Other plant alkaloids and natural products,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01CX01,trabectedin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DA,Actinomycines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DA01,dactinomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB01,doxorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB02,daunorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB03,epirubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB04,aclarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB05,zorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB06,idarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB07,mitoxantrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB08,pirarubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB09,valrubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB10,amrubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DB,Anthracyclines and related substances,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DB11,pixantrone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC01,bleomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC02,plicamycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC03,mitomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01D,CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES,L01DC,Other cytotoxic antibiotics,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01DC04,ixabepilone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA01,imatinib,NA,NA,NA,NA,0.4,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA02,dasatinib,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA03,nilotinib,NA,NA,NA,NA,0.6,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA04,bosutinib,NA,NA,NA,NA,0.4,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA05,ponatinib,NA,NA,NA,NA,45,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EA,BCR-ABL tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the standard starting dose in the treatment of chronic myeloid leukemia in early phase (chronic phase).",L01EA06,asciminib,NA,NA,NA,NA,80,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB01,gefitinib,NA,NA,NA,NA,0.25,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB02,erlotinib,NA,NA,NA,NA,0.15,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB03,afatinib,NA,NA,NA,NA,40,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB04,osimertinib,NA,NA,NA,NA,80,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB05,rociletinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB06,olmutinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB07,dacomitinib,NA,NA,NA,NA,45,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB08,icotinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB09,lazertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB10,mobocertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EB,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for erlotinib is based on the treatment of non-small cell lung cancer (NSCLC).",L01EB11,aumolertinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC01,vemurafenib,NA,NA,NA,NA,1.92,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC02,dabrafenib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EC,B-Raf serine-threonine kinase (BRAF) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for encorafenib is based on the treatment of melanoma.",L01EC03,encorafenib,NA,NA,NA,NA,0.45,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED01,crizotinib,NA,NA,NA,NA,0.5,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED02,ceritinib,NA,NA,NA,NA,0.45,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED03,alectinib,NA,NA,NA,NA,1.2,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED04,brigatinib,NA,NA,NA,NA,0.18,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01ED,Anaplastic lymphoma kinase (ALK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01ED05,lorlatinib,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE01,trametinib,NA,NA,NA,NA,2,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE02,cobimetinib,NA,NA,NA,NA,45,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE03,binimetinib,NA,NA,NA,NA,90,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EE,Mitogen-activated protein kinase (MEK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EE04,selumetinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF01,palbociclib,NA,NA,NA,NA,94,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF02,ribociclib,NA,NA,NA,NA,0.45,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EF,Cyclin-dependent kinase (CDK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EF03,abemaciclib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG01,temsirolimus,NA,NA,NA,NA,NA,3.57,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG02,everolimus,NA,NA,NA,NA,10,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG03,ridaforolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EG,Mammalian target of rapamycin (mTOR) kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EG04,sirolimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH01,lapatinib,NA,NA,NA,NA,1.25,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH02,neratinib,NA,NA,NA,NA,0.24,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EH,Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EH03,tucatinib,NA,NA,NA,NA,0.6,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ01,ruxolitinib,NA,NA,NA,NA,30,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ02,fedratinib,NA,NA,NA,NA,0.4,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ03,pacritinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EJ,Janus-associated kinase (JAK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDDs are based on the treatment of myelofibrosis.",L01EJ04,momelotinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK01,axitinib,NA,NA,NA,NA,10,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK02,cediranib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK03,tivozanib,NA,NA,NA,NA,1,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EK,Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EK04,fruquintinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL01,ibrutinib,NA,NA,NA,NA,0.42,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL02,acalabrutinib,NA,NA,NA,NA,0.2,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL03,zanubrutinib,NA,NA,NA,NA,0.32,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL04,orelabrutinib,NA,NA,NA,NA,0.15,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EL,Bruton's tyrosine kinase (BTK) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for ibrutinib is based on the treatment of chronic lymphocytic leukaemia (CLL) .",L01EL05,pirtobrutinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM01,idelalisib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM02,copanlisib,NA,NA,NA,NA,NA,6.43,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM03,alpelisib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM04,duvelisib,NA,NA,NA,NA,50,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EM,Phosphatidylinositol-3-kinase (Pi3K) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EM05,parsaclisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN01,erdafitinib,NA,NA,NA,NA,9,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN02,pemigatinib,NA,NA,NA,NA,9,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN03,infigratinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EN,Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01EN04,futibatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX01,sunitinib,NA,NA,NA,NA,33,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX02,sorafenib,NA,NA,NA,NA,0.8,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX03,pazopanib,NA,NA,NA,NA,0.8,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX04,vandetanib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX05,regorafenib,NA,NA,NA,NA,0.12,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX06,masitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX07,cabozantinib,NA,NA,NA,NA,60,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX08,lenvatinib,NA,NA,NA,NA,18,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX09,nintedanib,NA,NA,NA,NA,0.38,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX10,midostaurin,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX11,quizartinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX12,larotrectinib,NA,NA,NA,NA,0.2,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX13,gilteritinib,NA,NA,NA,NA,0.12,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX14,entrectinib,NA,NA,NA,NA,0.6,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX15,pexidartinib,NA,NA,NA,NA,0.8,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX17,capmatinib,NA,NA,NA,NA,0.8,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX18,avapritinib,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX19,ripretinib,NA,NA,NA,NA,0.15,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX21,tepotinib,NA,NA,NA,NA,0.45,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX22,selpercatinib,NA,NA,NA,NA,0.32,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX23,pralsetinib,NA,NA,NA,NA,0.4,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX24,surufatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX25,umbralisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX26,sitravatinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01E,PROTEIN KINASE INHIBITORS,L01EX,Other protein kinase inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents. The DDD for cabozantinib is based on the treatment (tablets) of renal cell carcinoma and hepatocellular carcinoma.The DDD for lenvatinib is based on the treatment of renal cell carcinoma.The DDD for midostaurin is based on the treatment of acute myeloid leukaemia (AML).",L01EX27,capivasertib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA01,rituximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA02,ofatumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FA,CD20 (Clusters of Differentiation 20) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FA03,obinutuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FB,CD22 (Clusters of Differentiation 22) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FB01,inotuzumab ozogamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FB,CD22 (Clusters of Differentiation 22) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FB02,moxetumomab pasudotox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FC,CD38 (Clusters of Differentiation 38) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FC01,daratumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FC,CD38 (Clusters of Differentiation 38) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FC02,isatuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD01,trastuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD02,pertuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD03,trastuzumab emtansine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD04,trastuzumab deruxtecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD05,trastuzumab duocarmazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FD,HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FD06,margetuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE01,cetuximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE02,panitumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FE,EGFR (Epidermal Growth Factor Receptor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FE03,necitumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF01,nivolumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF02,pembrolizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF03,durvalumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF04,avelumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF05,atezolizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF06,cemiplimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF07,dostarlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF08,prolgolimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF09,tislelizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF10,retifanlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF11,sugemalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF12,serplulimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FF,PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FF13,toripalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FG,VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FG01,bevacizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FG,VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FG02,ramucirumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX01,edrecolomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX02,gemtuzumab ozogamicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX03,catumaxomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX04,ipilimumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX05,brentuximab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX06,dinutuximab beta,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX07,blinatumomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX08,elotuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX09,mogamulizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX10,olaratumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX11,bermekimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX12,tafasitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX13,enfortumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX14,polatuzumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX15,belantamab mafodotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX16,oportuzumab monatox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX17,sacituzumab govitecan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX18,amivantamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX19,sabatolimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX20,tremelimumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX21,naxitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX22,loncastuximab tesirine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX23,tisotumab vedotin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX24,teclistamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX25,mosunetuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX26,mirvetuximab soravtansine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX27,epcoritamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX28,glofitamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FX,Other monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FX29,talquetamab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY01,pertuzumab and trastuzumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY02,nivolumab and relatlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01F,MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES,L01FY,Combinations of monoclonal antibodies and antibody drug conjugates,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01FY03,prolgolimab and nurulimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA01,cisplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA02,carboplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA03,oxaliplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA04,satraplatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XA,Platinum compounds,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XA05,polyplatillen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XB,Methylhydrazines,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XB01,procarbazine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD01,porfimer sodium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD03,methyl aminolevulinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD04,aminolevulinic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD05,temoporfin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD06,efaproxiral,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XD,Sensitizers used in photodynamic/radiation therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XD07,padeliporfin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF01,tretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF02,alitretinoin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XF,Retinoids for cancer treatment,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XF03,bexarotene,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG01,bortezomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG02,carfilzomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XG,Proteasome inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XG03,ixazomib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH01,vorinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH02,romidepsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH03,panobinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH04,belinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XH,Histone deacetylase (HDAC) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XH05,entinostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ01,vismodegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ02,sonidegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XJ,Hedgehog pathway inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XJ03,glasdegib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK01,olaparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK02,niraparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK03,rucaparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK04,talazoparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK05,veliparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK06,pamiparib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XK,Poly (ADP-ribose) polymerase (PARP) inhibitors,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XK52,niraparib and abiraterone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL01,sitimagene ceradenovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL02,talimogene laherparepvec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL03,axicabtagene ciloleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL04,tisagenlecleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL05,ciltacabtagene autoleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL06,brexucabtagene autoleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL07,idecabtagene vicleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL08,lisocabtagene maraleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL09,tabelecleucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL10,nadofaragene firadenovec,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XL,Antineoplastic cell and gene therapy,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XL11,lifileucel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX01,amsacrine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX02,asparaginase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX03,altretamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX05,hydroxycarbamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX07,lonidamine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX08,pentostatin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX10,masoprocol,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX11,estramustine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX16,mitoguazone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX18,tiazofurine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX23,mitotane,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX24,pegaspargase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX27,arsenic trioxide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX29,denileukin diftitox,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX33,celecoxib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX35,anagrelide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX36,oblimersen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX40,omacetaxine mepesuccinate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX41,eribulin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX44,aflibercept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX52,venetoclax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX53,vosaroxin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX57,plitidepsin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX58,epacadostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX59,enasidenib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX62,ivosidenib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX66,selinexor,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX67,tagraxofusp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX69,lurbinectedin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX72,tazemetostat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX73,sotorasib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX74,belzutifan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX75,tebentafusp,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX77,adagrasib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX78,navitoclax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX79,eflornithine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XX,Other antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XX80,imetelstat,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L01,ANTINEOPLASTIC AGENTS,L01X,OTHER ANTINEOPLASTIC AGENTS,L01XY,Combinations of antineoplastic agents,"DDDs have been established for the protein kinase inhibitors in L01E only.No DDDs have been established for substances classified in ATC 3rd level L01A, L01B, L01C, L01D, L01F or L01X.  This is because of highly individualised use and wide dosage ranges.  The doses used vary substantially because of various types and severity of neoplastic diseases, and also because of the extensive use of combination therapy.The consumption of antineoplastic agents is in some countries measured in grams.  This is recommended as a method to be used internationally for these particular agents.",L01XY01,cytarabine and daunorubicin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA01,diethylstilbestrol,NA,NA,NA,NA,3,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA02,polyestradiol phosphate,NA,NA,NA,NA,NA,6,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA03,ethinylestradiol,NA,NA,NA,NA,1.5,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AA,Estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AA04,fosfestrol,NA,NA,NA,NA,0.25,0.25,NA,NA,NA,g,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB01,megestrol,NA,NA,NA,NA,0.16,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB02,medroxyprogesterone,NA,NA,NA,NA,1,1,NA,NA,NA,g,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AB,Progestogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02AB03,gestonorone,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE01,buserelin,NA,0.11,NA,1.2,NA,1.5,mg,NA,mg,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE02,leuprorelin,depot inj,NA,NA,NA,NA,0.134,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE02,leuprorelin,NA,60,NA,NA,NA,1,mcg,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE03,goserelin,NA,0.129,NA,NA,NA,NA,mg,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE04,triptorelin,depot inj,NA,NA,NA,NA,0.134,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE04,triptorelin,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE05,histrelin,NA,0.137,NA,NA,NA,NA,mg,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AE,Gonadotropin releasing hormone analogues,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic). The DDD of 60 mcg for leuprorelin implant is based on 5 mg implant/90 days.The depot DDD for triptorelin is based on treatment of prostatic cancer while the other DDD of 0.1 mg is based on the dose in one syringe used in women undergoing controlled ovarian hyperstimulation.",L02AE51,leuprorelin and bicalutamide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02A,HORMONES AND RELATED AGENTS,L02AX,Other hormones,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA01,tamoxifen,NA,NA,NA,NA,20,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA02,toremifene,NA,NA,NA,NA,60,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA03,fulvestrant,NA,NA,NA,NA,NA,8.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BA,Anti-estrogens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BA04,elacestrant,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB01,flutamide,NA,NA,NA,NA,0.75,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB02,nilutamide,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB03,bicalutamide,NA,NA,NA,NA,50,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB04,enzalutamide,NA,NA,NA,NA,0.16,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB05,apalutamide,NA,NA,NA,NA,0.24,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BB,Anti-androgens,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BB06,darolutamide,NA,NA,NA,NA,1.2,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG01,aminoglutethimide,NA,NA,NA,NA,1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG02,formestane,NA,NA,NA,NA,NA,18,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG03,anastrozole,NA,NA,NA,NA,1,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG04,letrozole,NA,NA,NA,NA,2.5,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG05,vorozole,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BG,Aromatase inhibitors,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BG06,exemestane,NA,NA,NA,NA,25,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX01,abarelix,NA,NA,NA,NA,NA,3.6,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX02,degarelix,NA,NA,NA,NA,NA,2.7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX03,abiraterone,NA,NA,NA,NA,1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX04,relugolix,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L02,ENDOCRINE THERAPY,L02B,HORMONE ANTAGONISTS AND RELATED AGENTS,L02BX,Other hormone antagonists and related agents,"The DDDs are based on the treatment of cancer (breast-, endometrial, and prostatic).",L02BX53,abiraterone and prednisolone,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA02,filgrastim,NA,NA,NA,NA,NA,0.35,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA03,molgramostim,NA,NA,NA,NA,NA,0.35,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA09,sargramostim,NA,NA,NA,NA,NA,0.45,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA10,lenograstim,NA,NA,NA,NA,NA,0.35,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA12,ancestim,NA,NA,NA,NA,NA,1.4,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA13,pegfilgrastim,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA14,lipegfilgrastim,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA15,balugrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA16,empegfilgrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA17,pegteograstim,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA18,efbemalenograstim alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AA,Colony stimulating factors,The DDDs for pegfilgrastim (L03AA13) and lipegfilgrastim (L03AA14) are based on the declared amount of filgrastim and on the use of one single dose per cycle of chemotherapy. The DDDs for the other G-CSFs are based on daily dosing for six subsequent days.,L03AA19,eflapegrastim,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB01,interferon alfa natural,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,MU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB02,interferon beta natural,NA,NA,NA,NA,NA,33.33,NA,NA,NA,NA,TU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB03,interferon gamma,NA,NA,NA,NA,NA,40,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB04,interferon alfa-2a,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,MU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB05,interferon alfa-2b,NA,NA,NA,NA,NA,2,NA,NA,NA,NA,MU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB06,interferon alfa-n1,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,MU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB07,interferon beta-1a,NA,NA,NA,NA,NA,4.3,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB08,interferon beta-1b,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,MU
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB09,interferon alfacon-1,NA,NA,NA,NA,NA,4,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB10,peginterferon alfa-2b,NA,NA,NA,NA,NA,7.5,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB11,peginterferon alfa-2a,NA,NA,NA,NA,NA,26,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB12,albinterferon alfa-2b,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB13,peginterferon beta-1a,NA,NA,NA,NA,NA,8.9,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB14,cepeginterferon alfa-2b,NA,NA,NA,NA,NA,17,NA,NA,NA,NA,mcg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB15,ropeginterferon alfa-2b,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB16,peginterferon alfacon-2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB17,sampeginterferon beta-1a,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB60,"peginterferon alfa-2b, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AB,Interferons,"The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.The DDDs of interferon beta-1a is based on i.m. administration.",L03AB61,"peginterferon alfa-2a, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AC,Interleukins,The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.,L03AC01,aldesleukin,NA,NA,NA,NA,NA,0.2,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AC,Interleukins,The DDD for aldesleukin is based on the use of 5 vials (6.5 mg) per treatment cycle of 33 days.,L03AC02,oprelvekin,NA,NA,NA,NA,NA,3.5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX01,lentinan,NA,NA,NA,NA,0.3,0.3,NA,NA,NA,mg,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX02,roquinimex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX03,BCG vaccine,NA,NA,1.8,NA,NA,NA,NA,mg,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX04,pegademase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX05,pidotimod,NA,NA,NA,NA,1.6,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX07,poly I:C,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX08,poly ICLC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX09,thymopentin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX10,immunocyanin,NA,NA,3,NA,NA,NA,NA,mg,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX11,tasonermin,NA,NA,NA,NA,NA,3.5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX12,melanoma vaccine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX13,glatiramer acetate,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX14,histamine dihydrochloride,NA,NA,NA,NA,NA,0.5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX15,mifamurtide,NA,NA,NA,NA,NA,0.7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX16,plerixafor,NA,NA,NA,NA,NA,16.8,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX17,sipuleucel-T,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX18,cridanimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX19,dasiprotimut-T,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX21,elapegademase,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L03,IMMUNOSTIMULANTS,L03A,IMMUNOSTIMULANTS,L03AX,Other immunostimulants,The DDD for tasonermin is based on single dose treatment.The DDD of 0.5 mg (P) for histamine dihydrochloride is based on the total dose devided by days of first treatment cycle (42 days).,L03AX22,leniolisib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA03,antilymphocyte immunoglobulin (horse),NA,NA,NA,NA,NA,1.05,NA,NA,NA,NA,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA04,antithymocyte immunoglobulin (rabbit),NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA06,mycophenolic acid,as mycophenolate mofetil,NA,NA,NA,2,2,NA,NA,NA,g,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA15,alefacept,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA19,gusperimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA22,abetimus,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA24,abatacept,NA,NA,NA,NA,NA,27,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA28,belatacept,NA,NA,NA,NA,NA,12.5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA32,apremilast,NA,NA,NA,NA,60,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA40,cladribine,NA,NA,NA,NA,0.34,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA41,imlifidase,course dose,NA,NA,NA,NA,17.5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA48,belumosudil,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AA,Selective immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for abatacept is based on the treatment of rheumatoid arthritis.The DDD for cladribine is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AA58,efgartigimod alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB01,etanercept,NA,NA,NA,NA,NA,7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB02,infliximab,NA,NA,NA,NA,NA,3.75,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB03,afelimomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB04,adalimumab,NA,NA,NA,NA,NA,2.9,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB05,certolizumab pegol,NA,NA,NA,NA,NA,14,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB06,golimumab,NA,NA,NA,NA,NA,1.66,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AB,Tumor necrosis factor alpha (TNF-) inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for etanercept, infliximab and adalimumab are based on the treatment of rheumatoid arthritis.The DDD for cerolizumab pegol is based on the treatment of Crohns Disease.",L04AB07,opinercept,NA,NA,NA,NA,NA,7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC01,daclizumab,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC02,basiliximab,course dose,NA,NA,NA,NA,40,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC03,anakinra,NA,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC04,rilonacept,NA,NA,NA,NA,NA,23,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC05,ustekinumab,NA,NA,NA,NA,NA,0.54,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC07,tocilizumab,NA,NA,NA,NA,NA,20,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC08,canakinumab,NA,NA,NA,NA,NA,2.7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC09,briakinumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC10,secukinumab,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC11,siltuximab,NA,NA,NA,NA,NA,37,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC12,brodalumab,NA,NA,NA,NA,NA,15,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC13,ixekizumab,NA,NA,NA,NA,NA,2.9,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC14,sarilumab,NA,NA,NA,NA,NA,14.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC15,sirukumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC16,guselkumab,NA,NA,NA,NA,NA,1.79,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC17,tildrakizumab,NA,NA,NA,NA,NA,1.11,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC18,risankizumab,NA,NA,NA,NA,NA,1.67,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC19,satralizumab,NA,NA,NA,NA,NA,4.3,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC20,netakimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC21,bimekizumab,NA,NA,NA,NA,NA,5.7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC22,spesolimab,course dose,NA,NA,NA,NA,0.9,NA,NA,NA,NA,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC23,olokizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC24,mirikizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AC,Interleukin inhibitors,"The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDDs for anakinra and tocilizumab are based on the treatment of rheumatoid arthritis.The DDD for daclizumab is based on the treatment of multiple sclerosis.The DDDs for ustekinumab, ixekizumab, brodalumab, and risankizumab are based on the treatment of psoriasis.",L04AC25,levilimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD01,ciclosporin,NA,NA,NA,NA,0.25,0.25,NA,NA,NA,g,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD02,tacrolimus,NA,NA,NA,NA,5,5,NA,NA,NA,mg,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AD,Calcineurin inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AD03,voclosporin,NA,NA,NA,NA,47.4,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE01,fingolimod,NA,NA,NA,NA,0.5,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE02,ozanimod,NA,NA,NA,NA,0.92,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE03,siponimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE04,ponesimod,NA,NA,NA,NA,20,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AE,Sphingosine-1-phosphate (S1P) receptor modulators,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for fingolimod is based on the treatment of multiple sclerosis.,L04AE05,etrasimod,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF01,tofacitinib,NA,NA,NA,NA,10,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF02,baricitinib,NA,NA,NA,NA,3,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF03,upadacitinib,NA,NA,NA,NA,15,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF04,filgotinib,NA,NA,NA,NA,0.2,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF05,itacitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF06,peficitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF07,deucravacitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AF,Janus-associated kinase (JAK) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for tofacitinib is based on the treatment of rheumatoid arthritis.,L04AF08,ritlecitinib,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG01,muromonab-CD3,NA,NA,NA,NA,NA,5,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG02,efalizumab,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG03,natalizumab,NA,NA,NA,NA,NA,10,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG04,belimumab,NA,NA,NA,NA,NA,25,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG05,vedolizumab,NA,NA,NA,NA,NA,5.4,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG06,alemtuzumab,NA,NA,NA,NA,NA,0.13,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG07,begelomab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG08,ocrelizumab,NA,NA,NA,NA,NA,3.29,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG09,emapalumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG10,inebilizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG11,anifrolumab,NA,NA,NA,NA,NA,10.7,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG12,ofatumumab,NA,NA,NA,NA,NA,0.67,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG13,teprotumumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG14,ublituximab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG15,divozilimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AG,Monoclonal antibodies,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.The DDD for efalizumab is based on the treatment of psoriasis.The DDDs for natalizumab and alemtuzumab are based on the treatment of multiple sclerosis.The DDD for alemtuzumab is based on the average calculated daily dose in the first two years (year 1 and 2) when all patients receive medication.,L04AG16,rozanolixizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AH,Mammalian target of rapamycin (mTOR) kinase inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AH01,sirolimus,NA,NA,NA,NA,3,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AH,Mammalian target of rapamycin (mTOR) kinase inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.,L04AH02,everolimus,NA,NA,NA,NA,1.5,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ01,eculizumab,NA,NA,NA,NA,NA,64,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ02,ravulizumab,NA,NA,NA,NA,NA,58.9,NA,NA,NA,NA,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ03,pegcetacoplan,NA,NA,NA,NA,NA,0.3,NA,NA,NA,NA,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ04,sutimlimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ05,avacopan,NA,NA,NA,NA,60,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ06,zilucoplan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ07,crovalimab,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ08,iptacopan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AJ,Complement inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for eculizumab is based on the dose given in the maintenance phase.,L04AJ09,danicopan,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AK,Dihydroorotate dehydrogenase (DHODH) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for leflunomide is based on the treatment of rheumatoid arthritis.The DDD for teriflunomide is based on the treatment of multiple sclerosis.,L04AK01,leflunomide,NA,NA,NA,NA,20,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AK,Dihydroorotate dehydrogenase (DHODH) inhibitors,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for leflunomide is based on the treatment of rheumatoid arthritis.The DDD for teriflunomide is based on the treatment of multiple sclerosis.,L04AK02,teriflunomide,NA,NA,NA,NA,14,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX01,azathioprine,NA,NA,NA,NA,0.15,0.15,NA,NA,NA,g,g
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX02,thalidomide,NA,NA,NA,NA,0.1,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX03,methotrexate,NA,NA,NA,NA,2.5,2.5,NA,NA,NA,mg,mg
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX04,lenalidomide,NA,NA,NA,NA,10,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX05,pirfenidone,NA,NA,NA,NA,2.4,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX06,pomalidomide,NA,NA,NA,NA,3,NA,NA,NA,NA,mg,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX07,dimethyl fumarate,NA,NA,NA,NA,0.48,NA,NA,NA,NA,g,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX08,darvadstrocel,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
L,ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS,L04,IMMUNOSUPPRESSANTS,L04A,IMMUNOSUPPRESSANTS,L04AX,Other immunosuppressants,The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication. The DDD for thalidomide is based on the treatment of lepra.The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.,L04AX09,diroximel fumarate,NA,NA,NA,NA,0.924,NA,NA,NA,NA,g,NA
